This article discusses how cancer care remains overly dependent on one-size-fits-all protocols and population averages, which often fail individual patients due to biological variability. The article emphasizes that the real opportunity in oncology lies in functional precision medicine (FPM) that directly tests a patient’s live tumor cells against a wide range of drugs and combinations ex vivo.